Table 1.
Baseline, 2‐ and 6‐year characteristics of the sample
| Baseline | 2‐Year follow‐up | 6‐Year follow‐up | |
|---|---|---|---|
| Characteristic | (total N = 2,776) | (total N = 2,203) | (total N = 1,899) |
| Sociodemographic and lifestyle characteristics | |||
| Age (years; mean, SD) | 41.8 (13.1) | 44.3 (13.1) | 48.20 (13.2) |
| Male (N, %) | 946 (34.1) | 756 (34.3) | 654 (34.4) |
| Education (years; mean, SD) | 12.2 (3.3) | 12.6 (3.3) | 13.0 (3.3) |
| Physical activity (total MET‐minutes/week; mean, SD) | 3,674.1 (3,120.3) | 4,050.5 (3,416.5) | 3,905.9 (3,415.2) |
| Current smoking (N, %) | 1,065 (38.4) | 667 (30.3) | 625 (21.0) |
| Alcohol use (N, %) | |||
| None | 885 (31.9) | 694 (31.5) | 535 (28.2) |
| Moderate | 1,573 (56.7) | 1,276 (57.9) | 1,198 (63.1) |
| Heavy | 318 (11.5) | 233 (10.6) | 166 (8.7) |
| Body mass index (mean, SD) | 25.6 (5.0) | 25.8 (4.9) | 26.2 (5.1) |
| Body mass categories (N, %) | |||
| Underweight | 65 (2.3) | 39 (1.8) | 32 (1.7) |
| Normal weight | 1,405 (50.6) | 1,084 (49.2) | 860 (45.3) |
| Overweight | 840 (30.2) | 687 (31.2) | 635 (33.4) |
| Obese | 466 (16.8) | 393 (17.8) | 372 (19.6) |
| Metabolic syndrome | |||
| Metabolic syndrome present (N, %) | 505 (17.2) | 454 (20.0) | 454 (22.8) |
| Number of metabolic syndrome abnormalities (mean, SD) | 1.4 (1.2) | 1.4 (1.3) | 1.5 (1.3) |
| Waist circumference (cm; mean, SD) | 89.0 (14.0) | 89.7 (14.3) | 92.2 (13.8) |
| HDL cholesterol (mmol/L; mean, SD)a | 1.6 (0.4) | 1.5 (0.4) | 1.6 (0.4) |
| Triglycerides (mmol/L; median, IQR)a | 1.1 (0.8) | 1.1 (0.8) | 1.1 (0.8) |
| SBP (mmHg; mean, SD)a | 128.3 (17.5) | 132.1 (18.1) | 133.0 (18.3) |
| Glucose (mmol/L; median, IQR)a | 5.0 (0.9) | 5.2 (0.8) | 5.3 (0.8) |
| Psychopathology | |||
| Diagnoses in previous 6 months (N, %) | |||
| Current disorder | 1,572 (56.6) | 808 (36.7) | 538 (28.3) |
| Depression | 1,066 (38.4) | 519 (23.6) | 346 (18.2) |
| Anxiety | 1,202 (43.3) | 593 (26.9) | 373 (19.6) |
| Remitted disorder | 589 (21.2) | 922 (41.9) | 954 (50.2) |
| Healthy controls | 615 (22.1) | 473 (21.5) | 407 (21.4) |
| IDS (mean, SD) | |||
| Overall | 21.4 (14.1) | 15.6 (11.8) | 15.1 (11.8) |
| Among those with current disorder | 29.2 (12.5) | 25.0 (12.1) | 26.1 (12.2) |
| Among those with remitted disorder | 14.2 (8.9) | 12.6 (8.3) | 13.0 (8.8) |
| Among healthy controls | 8.6 (7.5) | 6.2 (5.4) | 5.9 (5.3) |
| BAI (mean, SD) | |||
| Overall | 12.0 (10.6) | 8.6 (8.6) | 8.4 (8.5) |
| Among those with current disorder | 17.1 (10.8) | 14.5 (9.6) | 15.7 (10.0) |
| Among those with remitted disorder | 7.2 (6.5) | 6.4 (6.2) | 6.7 (6.1) |
| Among healthy controls | 4.1 (4.8) | 3.0 (3.8) | 3.0 (3.8) |
| Fear questionnaire (mean, SD) | |||
| Overall | 24.7 (19.9) | 19.1 (17.5) | 17.3 (17.1) |
| Among those with current disorder | 32.8 (20.6) | 30.6 (19.9) | 30.5 (19.8) |
| Among those with remitted disorder | 16.7 (13.2) | 14.7 (13.1) | 14.1 (13.6) |
| Among healthy controls | 12.0 (12.2) | 9.2 (9.0) | 8.0 (9.3) |
| Antidepressants (N, %) | |||
| Tricyclic antidepressants | 73 (2.6) | 64 (3.0) | 60 (3.2) |
| SSRIs | 467 (16.8) | 307 (14.5) | 221 (11.6) |
| Other antidepressants | 157 (5.7) | 112 (5.3) | 92 (4.8) |
| No antidepressants | 2,054 (74.0) | 1,631 (77.2) | 1,521 (80.1) |
a
Adjusted for use of medications with metabolic effects.